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Oncology 
Ibrutinib (Imbruvica ™) for Treatment of Mantle Cell Lymphoma 
Brittany Crowe, fifth-year pharmacy student from New Springfield, Ohio; Joy Hoffman, fourth-year pharmacy student from 
Fremont, Ohio; Hannah Stewart, fourth-year pharmacy student from Brazil, Ind.; Alison Steinbrunner, fifth-year pharmacy 
student from New Carlisle, Ohio; Mark E. Olah, Ph.D., associate professor of pharmacology, chair of the department of 
pharmaceutical and biomedical sciences 
This knowledge-based activity is targeted for all pharmacists 
and is acceptable for .5 hour (.05 CEU) of continuing 
education credit. This course requires completion 
of the program evaluation and at least a 70 percent grade 
on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-14-173-HO 1-P 
Objectives 
After completion of this program, the reader should be able 
to: 
1. Identify current first-line treatments for mantle cell 
lymphoma (MCL) when considering functional status 
of the patient and stage of the cancer. 
2. Explain the importance of MCL cell migration, as 
seen in ex vivo study of ibrutinib. 
3. Describe the pharmacology of ibrutinib. 
4. Discuss the benefits of ibrutinib treatment in re-
lapsed/refractory MCL observed in phase II develop-
ment. 
5. State key patient counseling points, including side 
effects and dosing ofibrutinib for MCL. 
Abstract 
Mantle cell lymphoma (MCL) is a rare and moderately ag-
gressive form of non-Hodgkin's lymphoma (NHL) that pre-
dominantly presents at an advanced stage in older males. 
Patients often present with multiple involvement in the 
lymph nodes, blood, spleen, bone marrow and gastrointesti-
nal tract (GIT). Some patients may be asymptomatic in early 
stages or present with an incurable, indolent (slow progress-
ing) form, while other patients display rapid growth of more 
aggressive lymphomas. Overall survival for patients diag-
nosed with MCL is four to five years and treatment should be 
initiated in those who are symptomatic. Mantle cell lym-
phoma responds well to first-line treatment, but recurrent 
relapses are common, and no regimen has been proven supe-
rior for relapsed or refractory MCL. The U.S. Food and Drug 
Administration (FDA) has recently approved ibrutinib 
(lmbruvica™) as breakthrough MCL therapy. lbrutinib is a 
Bruton's tyrosine kinase (BTK) inhibitor that interferes with 
malignant B-cell proliferation and survival. In a recent clini-
cal study, ibrutinib proved to be a highly active monotherapy 
with a favorable toxicity profile in 111 patients with relapsed 
or refractory MCL. As an oral chemotherapy drug, ibrutinib 
has the potential to improve patient compliance. Addition-
ally, specialty pharmacies dispensing ibrutinib will be able to 
play an important role in patient counseling and monitoring. 
Introduction to Mantle Cell Lymphoma 
Mantle cell lymphoma (MCL) is a rare form of NHL with 
about 4,000 new cases each year in the United States.1.2 Most 
patients with MCL present at the advanced stages, stage lII 
and IV, with lymphadenopathy that is generalized and not 
bulky.1 The lymphoma will likely affect multiple tissues and 
organs including lymph nodes, blood, spleen, and bone 
marrow, and lymphomatoid polyposis, which are lymphoid 
polyps in the gastrointestinal tract (GIT), may be present.3 
Clinically, a patient with MCL may present with enlarged 
lymph nodes, swollen abdomen, chest pain or pressure, or 
satiety after a small amount of food due to enlarged tonsils, 
liver or spleen. Presentation may also include dyspnea, fever, 
unexplained weight loss, nausea and vomiting, fatigue due to 
anemia or drenching night sweats.2,4 MCL presents most 
commonly at a moderately aggressive stage in men in their 
fifth and sixth decades of life.1 
If a patient presents with suspected MCL, a tumor biopsy is 
performed to confirm diagnosis.1 An MCL biopsy lacks blastic 
cell involvement, but otherwise resembles other lymphomas. 
Cyclin Dl overexpression, elevated lactate dehydrogenase, 
and beta-2 microglobulin may assist in diagnosis of MCL.S 
Overexpression of cyclin Dl, a promoter of cell cycle progres-
sion, is present in up to 90 percent of MCL cases, due to a 
(11;14) chromosomal translocation involving IgH and cyclin 
Dl loci.3 Elevated levels of lactate dehydrogenase and beta-2 
microglobulin are present in 25 to SO percent of patients 
with MCL.S,6 About 20 percent of MCL patients will progress 
to an incurable, indolent lymphoma, accompanied by the 
rapid growth of aggressive lymphomas.I This unique presen-
tation of MCL contributes to a general life expectancy of four 
to five years past the diagnosis. Patients in this stage will 
often present similarly to chronic lymphocytic leukemia 
(CLL), having a lymphadenopathy that is slow to progress 
and a low tumor count.7 If asymptomatic, the patient should 
be observed; however, in symptomatic patients who present 
with bulky lymphadenopathy or splenomegaly, constitu-
tional symptoms, or present with cytopenia requiring trans-
fusion, treatment is required. 
Current Treatments 
First-line treatments for MCL vary according to the physical 
status of the patient. Stem cell transplants are the first-line 
treatment for patients who are younger than 65 years and 
have good performance status, as they are more likely to tol-
erate this intensive treatment.7 These patients receive high-
dose chemotherapy (HDT), including Ara-C and rituximab, 
followed by an autologous stem cell transplantation (ASCT).1 
In eligible patients, this treatment is recommended once, and 
provides a longer time to treatment failure (TTF) and im-
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proved overall survival (OS) as compared to protocols that 
do not utilize rituximab. 
Many patients, however, present at late stages of MCL and/or 
may not be eligible for a transplant.1 Radiation therapy is 
usually ineffective at late stages and, therefore, chemother-
apy is the mainstay of treatment. 7 Generally, patients receive 
the R-CHOP regimen, which consists of rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone.1 This 
therapy increases overall response rate (ORR), the percent-
age of patients whose cancer responds favorably to the 
treatment, and complete response (CR) in which all signs of 
cancer are eliminated due to treatment, but there is no im-
provement in os.1.a While other treatment regimens are 
available, R-CHOP therapy has the best evidence.1 
First-line treatments for MCL are often successful, but nearly 
all patients will relapse within two years.1 The high relapse 
rate has directed research to identify novel therapies. While 
no regimen has yet been shown superior, many agents are 
currently undergoing clinical trials. Bortezomib is a pro-
teosome inhibitor with an ORR of 33 percent.21.7 Temsi-
rolimus and other mammalian target of rapamycin (mTOR) 
inhibitors are also being studied and have an ORR of 22 per-
cent. Lenalidomide is an immunomodulator with an ORR of 
53 percent. Jbrutinib is a Bruton's tyrosine kinase (BTK) in-
hibitor with an ORR of 68 percent, CR of 22 percent, and par-
tial response (PR), a decrease in tumor size or cancer extent 
due to treatment, of 46 percent. Jbrutinib was recently FDA 
approved for the treatment of relapsed MCL and is the focus 
of this article.9 
Ibrutinib Pharmacology and Pharmacokinetics 
lbrutinib was approved in November 2013, for treatment of 
MCL in patients who have been treated at least once previ-
ously.9 Jbrutinib was also approved in February 2014, for 
chronic lymphocytic leukemia in patients who have received 
one prior therapy.10 This paper will focus on the indication 
for MCL, which was approved via the accelerated approval 
program, as ibrutinib received breakthrough therapy desig-
nation.9,11 Ibrutinib inhibits BTK, a terminal non-receptor 
tyrosine kinase, which promotes downstream activity of 
growth factors, 8-cell antigens, chemokines and innate 
immune receptors.12 Normally, BTK signaling promotes 
development, differentiation, and functioning of 8-cells. By 
inhibiting BTK, ibrutinib inhibits proliferation of the lym-
phoma in MCL. 
Ibrutinib inhibits kinase activity of BTK through covalent 
binding to the non-catalytic cys-481 residue of BTK, which is 
present in only 10 other kinases at this exact position.13 
Therefore, ibrutinib is a fairly selective inhibitor of BTK, be-
ing 1,000 times more selective for BTK of 8-cells than CD69 
of T-cells. Ibrutinib irreversibly inhibits BTK-driven gene 
expression. When compared with a known reversible inhibi-
tor of BTK, ibrutinib inhibited gene up-regulation following a 
washout period while the reversible inhibitor did not. In vi-
tro, one-hour exposure compared to continuous exposure to 
ibrutinib has the same inhibitory activity, demonstrating that 
one-time exposure is sufficient to inhibit BTK. Ibrutinib is 
relatively potent with an JCso of 0.5 nM. 
In vitro, ibrutinib appears to induce apoptosis of B-cells by 
two main mechanisms: inhibiting anti-apoptotic mechanisms 
and stimulating pro-apoptotic mechanisms. First, ibrutinib 
blocks anti-apoptotic pathways by decreasing ERK phos-
phorylation, decreasing NF-kB signaling, and decreasing ex-
pression of Akt, a serine threonine kinase that promotes cell 
cycle progression.14-18 Secondly, ibrutinib stimulates pro-
apoptotic mechanisms in B-cells by activating caspases.14 
Additionally, ibrutinib decreases anti-JgM-induced signaling 
that stimulates B-cells by decreasing adhesion to VCAM, an 
adhesion molecule, and fibronectin, a glycoprotein involved 
in adhesion and migration.11,19,20 Ibrutinib also decreases 
signaling induced by chemokines such as CXCL-12 and CXCL-
13, that are secreted by stromal cells, and decreases produc-
tion of cytokines such as interleukin-10.1s,11,21 By interfering 
with this signaling, ibrutinib inhibits the migration, adhesion, 
and proliferation of malignant B-cells. 
The cellular mechanisms of ibrutinib that were delineated in 
vitro were substantiated in a study published by Chang and 
colleagues.22 This study provided ex vivo insight to the 
mechanism of action of the anti-tumor effect of ibrutinib by 
examining the migration of MCL cells from the tumor into the 
peripheral blood and the characteristics of these malignant 
cells once in the periphery. Phenotyping, adhesion molecule 
assessments and migration assays were performed on blood 
samples collected from 22 patients participating in ibrutinib 
clinical trials. Following ibrutinib treatment, there was a sta-
tistically significant increase in the absolute lymphocyte 
count (ALC) in the peripheral blood, demonstrating the mi-
gration of malignant cells to the periphery, which contributes 
to the death of these cells. The lymphocytes tested, CDl 9 and 
CDS, had a decreased expression of CXCR4, CD38, and Ki57, 
all of which are surface molecules necessary for successful 
cell cycle progression. lbrutinib suppressed the B-cell recep-
tor (BCR)-stimulated cytokine and chemokine production 
from MCL cells and inhibited BCR-stimulated adhesion of 
MCL cells. 
By inhibiting adhesion molecule expression, chemokine pro-
duction and the downstream signaling of BTK, ibrutinib ther-
apy forces malignant cells to migrate from their host tissue 
and enter the peripheral blood.22 These micro events were 
further documented at the macro level as the lymph tissue 
mass clinically decreased. lbrutinib decreased expression of 
CXCR4, a protein necessary for chemotaxis of malignant cells 
back to preferred tissues. The entrance and maintenance of 
malignant cells in the periphery is important because the 
MCL cells meet their demise in the peripheral blood. In the 
periphery, these cells do not have soluble factor exposure 
and other necessary components for proliferation and sur-
vival, and consequently, the malignant cells die and are 
cleared from the body. This study is important as it shows 
the mechanisms of anti-tumor action of ibrutinib and pro-
vides micro level insight of the positive macro level clinical 
results. 
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Pharmacokinetic studies on ibrutinib have also been con-
ducted. Without food, the T max of ibrutinib is approximately 
one to two hours, with an area under the curve (AUC) of 
953 ng*h/mL at steady state.23 In the body, the drug is highly 
protein bound, evidenced by a volume of distribution of 
10,000 L at steady state. Ibrutinib is primarily metabolized 
by CYP3A4, with some metabolism via CYP206. The half-life 
of ibrutinib is four to six hours, and the majority of metabo-
lites are excreted in feces. 
Clinical Study 
A phase II open-label, non-randomized, multicenter, mono-
therapy study by Wang and colleagues investigated the use 
of oral ibrutinib in 111 patients with relapsed or refractory 
MCL.24 Other clinical trials are currently in progress, but the 
accelerated approval of ibrutinib was based on this trial.9,25 
The study enrolled subjects into two cohort groups based on 
their treatment history.24 The first group included subjects 
who had previously received at least two, but not more than 
five, cycles of bortezomib therapy, while the second group 
included those who had received less than two complete cy-
cles or no prior bortezomib therapy. Eligible patients were 
required to have a confirmed diagnosis of MCL. Diagnosis 
was based on either cyclin 01 overexpression or chromoso-
mal translocation break points and an increase in lymph 
node diameter as a measure of staging the disease. 
The primary end point was ORR, defined as the proportion of 
study subjects who achieved either complete or partial re-
mission as their best overall response as defined by the 
modified Revised Response Criteria for Malignant 
Lymphoma.24,26 According to the Response Criteria, complete 
remission was the disappearance of all evidence of disease, 
and partial remission was regression of measurable disease 
with no new sites.27 Efficacy, safety, pharmacokinetics, and 
patient-reported outcomes regarding quality of life were all 
considered as secondary end points.26 Subjects received 
560 mg of oral ibrutinib daily in 28-day cycles until progres-
sion of the disease or an unacceptable level of adverse events 
was observed.24 The timing of patient visits and assessments 
were based on the treatment cycles.26 
The response rate for all patients was 68 percent, which in-
cluded a partial response in 4 7 percent of subjects and a 
complete response in 21 percent.24 The response rate did not 
vary with baseline characteristics or risk factors among the 
111 subjects. Based on near equivalence of response be-
tween the two cohorts, the ORRs were reported together as a 
single percentage. The median time to a response was 1.9 
months, the estimated median response duration was 17.5 
months, and the estimated median progression-free survival 
was 13.9 months among all treated. The National Cancer In-
stitute's Common Terminology Criteria for Adverse Events 
version 4.0 were used to evaluate adverse events.26 The cri-
teria include a scale of grades corresponding with the sever-
ity of adverse events: grade 1 (mild), grade 2 (moderate), 
grade 3 (severe or medically significant but not immediately 
life threatening), grade 4 (life threatening), and grade 5 
(death related to adverse events).28 The majority of the ad-
verse events observed with ibrutinib treatment were classi-
fled as grade 1 or grade 2, while grades 3, 4 and 5 were un-
common.24 Over 20 percent of patients experienced mild side 
effects such as diarrhea, fatigue, nausea, peripheral edema, 
dyspnea, constipation, upper respiratory tract infection, 
vomiting and decreased appetite. 
Peripheral blood lymphocytes were characterized post-
ibrutinib treatment, and it was found that 34 percent of sub-
jects had an increase in ALC that decreased and then tapered 
off by cycle 4 or cycle 5.24 The increase included mostly 
CD19+CD5+CD3- lymphocytes with a pattern of light chain 
restriction that is consistent with MCL cells in peripheral 
blood. Investigators also found that ibrutinib caused a de-
crease in the secretion of macrophage inflammatory proteins 
1-alpha (CCL3) and 1-beta (CCL4 ), macrophage-derived 
chemokine (CCL22) and TNF-alpha in most patients. 
In a separate study, Chang and colleagues effectively demon-
strated the ability of ibrutinib to inhibit the adhesion of MCL 
cells ex vivo, resulting in their mobilization to the peripheral 
blood.22 Similar inhibitory effects were observed with in vi-
tro ibrutinib treatment for CLL.29 Wang and colleagues cited 
these findings as part of their reasoning for investigating the 
presence of MCL cells in the peripheral blood of study sub-
jects. The ex vivo analysis, conducted by investigators within 
the in vivo study, also indicated that ibrutinib caused a tran-
sient increase in blood lymphocytes as well as a decrease in 
the secretion of certain inflammatory molecules.24 Therefore, 
the phase II trial by Wang and colleagues demonstrates the 
benefit of ibrutinib treatment on a micro level in study sub-
jects who also exhibited favorable macro level effects such as 
high response rate accompanied with a favorable level of 
toxicity. These effects indicate that ibrutinib has the potential 
to be a less intensive but more effective regimen than other 
treatments available for relapsed and refractory MCL. 
Investigators in this phase II trial concluded that ibrutinib is 
a highly active, single agent with considerable duration of 
activity in relapsed and refractory MCL along with a favor-
able toxicity profile.24 A major strength in the study design 
was the combination of two cohorts that allowed representa-
tion of a broad population of subjects with relapsed or re-
fractory MCL within a moderately small sample size. Patients 
receiving ibrutinib demonstrated statistically and clinically 
significant data indicating the potential for ibrutinib as a new 
treatment for relapsed and refractory MCL. 
Pharmacist Focus 
Dosing for ibrutinib is 560 mg daily, which equates to four 
140 mg capsules once daily. Dosing is based on evidence 
from the previously discussed clinical trial.24 lbrutinib may 
cause fetal harm in pregnant women and secretion into 
breast milk is unknown, as therapy should be carefully con-
sidered in the affected population.23 Concurrent CYP3A in-
ducers should be avoided, as they can decrease the plasma 
concentration of ibrutinib. Concurrent CYP3A4 inhibitors 
increase the risk of toxicity by increasing the AUC and Cmax of 
ibrutinib, and ibrutinib should be discontinued if short-term 
therapy with a CYP3A4 inhibitor is utilized. 
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An advantage of ibrutinib is a more favorable adverse effect 
profile for certain patient populations in comparison to other 
agents for relapsed MCL including bortezomib, temsirolimus 
and lenalidomide. The more severe adverse effects of these 
drugs include profound myelosuppression, anemia, cardiac 
effects, metabolic acidosis and hepatotoxicity.30-32 Serious 
adverse effects of ibrutinib include hemorrhage, infections, 
myelosuppression, renal toxicity and risk of secondary pri-
mary malignancies.23 While ibrutinib still exhibits serious 
adverse effects, it is a preferred choice for patients who have 
cardiac or hepatic complications. 
Being an oral chemotherapy agent, ibrutinib has many bene-
fits acknowledged by health care providers. These benefits 
include patient convenience and comfort, more favorable 
risk-benefit profiles and the availability of specialty pharma-
cies to help with reimbursement challenges and financial 
assistance and are among the top reasons oncologists would 
be more likely to prescribe an oral chemotherapy agent over 
an intravenous (IV) agent.33,34 
Another benefit of oral ibrutinib is the ability of patients to 
utilize outpatient services to obtain the medication. In regard 
to outpatient pharmacy services, specialty pharmacies, as 
previously mentioned, are expected to be often utilized. 
While their place in care is evolving, specialty pharmacies are 
essentially "niche" pharmacies.35 As defined by Scott Kober, 
"[Specialty pharmacy] serve[s] a limited number of patients 
with a small number of high-cost, low-volume and high-
maintenance conditions .... "35 These pharmacies offer special 
services such as high-quality counseling and assistance in 
navigating payment options for treatment.34,36 As an oral 
chemotherapy agent, ibrutinib will likely be frequently dis-
pensed at specialty pharmacies. 
Conclusion 
There is a need for effective chemotherapy agents that can be 
used to treat relapsed or refractory cases of MCL. Molecu-
larly targeted drugs such as bortezomib, temsirolimus and 
lenalidomide have shown anti-lymphoma activity useful in 
treating difficult cases of MCL.6 As a BTK inhibitor, ibrutinib 
also works on a molecular level to interfere in the malignant 
8-cell signaling cascade.6.22 Clinical trials have shown impres-
sive response rates for this newly introduced therapy.24 
Treatment with ibrutinib offers advantages including oral 
route of administration and a favorable toxicity profile com-
pared to other more intensive treatments. Furthermore, 
some oncologists have indicated that they prefer oral chemo-
therapies over IV regimens, with one reason being the role 
that specialty pharmacies may then take in optimizing pa-
tient care through counseling and monitoringJ.33,34 Although 
MCL is a moderately aggressive form of NHL, high response 
rates with ibrutinib therapy offers patients a chance for pro-
gression-free survival when first-line therapies have failed. 
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Ibrutinib (lmbruvica'M) for Treatment of Mantle Cell Lymphoma Oncology 
Assessment Questions 
1. KL is a 68 year old male with poor functional status who 
has recently been diagnosed with late stage MCL. He is 
about to start his first treatment. Which of the following 
is the most appropriate treatment regimen for him? 
A. External beam radiation therapy 
B. Ibrutinib x 28 day trial 
C. Rituximab + cyclophosphamide + doxorubicin + 
vincristine + prednisone (R-CHOP) 
D. Stem cell transplantation 
E. More than one of the above 
2. Which of the following CORRECTLY describes the impor-
tance of MCL cell migration? 
A. By inhibiting adhesion molecule expression, 
MCL cells are forced to enter peripheral blood. 
B. Ibrutinib decreases expression of CXCR4, which 
prevents malignant cells' return to their tissues. 
C. Once in the periphery, MCL cells do not have the 
necessary components for survival and die. 
D. Two of the above 
E. Three of the above 
3. TR is a 57 year old female coming to your specialty phar-
macy. She has arrived to pick up her new prescription 
for ibrutinib to treat her relapsed MCL. While excited 
that there are no needles involved with this drug, she is 
nervous about starting the new treatment and any ad-
verse effects it might bring. What counseling points 
about the adverse effects do you offer her? 
A. "You may bleed more easily. Take care to avoid 
injury." 
B. "If you feel very tired or weak, have an upset 
stomach, have a fast heartbeat or are breathing 
fast, call your doctor. These may be signs of too 
much acid in your blood." 
C. "This drug makes you more likely to catch ill-
nesses, such as the flu or a cold. Stay away from 
people who are sick." 
D. Two of the above 
E. Three of the above 
4. lbrutinib works by inhibiting which protein? 
A. Proteasome 
B. CDZO 
C. Bruton's tyrosine kinase 
D. Epidermal growth factor receptor 
E. Cyclin Dl 
5. What is the dosing of ibrutinib for MCL? 
A. 560 mg daily 
B. 140 mgTID 
C. 560 mg BID 
D. 280 mg daily 
E. 280 mg BID 






E. Ibrutinib is excreted unchanged in urine 
7. Which of the following statements accurately describes 
the toxicity profile associated with ibrutinib: 
A. Ibrutinib is not associated with a high occur-
rence of severe side effects such as grade 4 hem-
orrhagic events. 
B. Patients taking ibrutinib most commonly experi-
ence grade 1 or 2 adverse events. 
C. Possible side effects of ibrutinib include diar-
rhea, fatigue, dyspnea, and decrease in appetite. 
D. Two of the above 
E. Three of the above 
8. What were the major advantages associated with 
ibrutinib treatment in the main phase II clinical trial util-
ized for accelerated FDA approval? 
A. All participants achieved a complete response. 
B. Ibrutinib was found to be a highly active, single 
agent. 
C. Ibrutinib therapy had a considerable duration of 
action. 
D. Two of the above 
E. Three of the above 
9. During clinical development, both ex vivo and in vivo 
research indicated that ibrutinib had the potential to be 
a less intensive but more effective regimen than other 
treatments currently available. 
A. True 
B. False 
10. The protein target of ibrutinib normally has what func-
tion in a healthy body? 
A. Induces apoptosis of B-cells 
8. Stimulates chemokine release 
C. Promotes B-cell development 
D. Two of the above 
E. Three of the above 
Ohio Northern University is accredited by the 
Accreditation Council for Pharmacy Education as a 
provider of continuing pharmacy education. This 
program is eligible for credit until 05/07/2017. 
To receive continuing education credit for this program, you 
must answer the above questions and fill out the evaluation 
form. Please visit www.onu.edu/pharmacy to enter the 
required information. Please allow two to three weeks for 
electronic distribution of your continuing education certifi-
cate, which will be sent to your valid email address in PDF 
format. 
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To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below 
including your indicated answers to the assessment questions and return to: 
Office of Continuing Education at the Raabe College of Pharmacy 
Ohio Northern University 
525 South Main Street 
Ada, Ohio 45810 
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UAN: 0048-0000·14·173-HOl-P CEUs: .05 
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of 





Pharmacy License #: State: 
The program objectives were clear. 
The program met the stated goals and objectives: 
Identify current first-line treatments for mantle cell lymphoma (MCL) 
when considering functional status of the patient and stage of the 
cancer. 
Explain the importance of MCL cell migration, as seen in ex vivo study 
of ibrutinib. 
Describe the pharmacology of ibrutinib. 
Discuss the benefits of ibrutinib treatment in relapsed/refractory 
MCL observed in phase II development. 
State key patient counseling points, including side effects and dosing 
of ibrutinib for MCL. 
The program met your educational needs. 
Content of the program was interesting. 
Material presented was relevant to my practice. 



















































Answers to Assessment Questions-Please Circle Your Answer 
1. A B c D E 4. A B c D E 7. A B c D E 10. A B c D E 
2. A B c D E 5. A B c D E 8. A B c D E 
3. A B c D E 6. A B c D E 9. A B 
Any questions/comments regarding this continuing education program can ~- Ohio Northern University is accredited by the be directed to Lauren Hamman, Advanced Administrative Assistant for the Accreditation Council for Pharmacy Education as a Office of Continuing Education (email : 1-hamman(c/'onu.edu, phone 419- provider of continuing pharmacy education. This 772-2280). program is eligible for credit until 05/07/2017. 
